aTyr Pharma (NASDAQ:ATYR) Posts Earnings Results

aTyr Pharma (NASDAQ:ATYR) issued its quarterly earnings data on Friday. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05, FiscalAI reports.

aTyr Pharma Trading Down 10.0%

ATYR stock opened at $0.50 on Friday. aTyr Pharma has a 12 month low of $0.40 and a 12 month high of $7.29. The company has a 50-day moving average price of $0.81 and a 200 day moving average price of $0.81. The stock has a market cap of $49.42 million, a PE ratio of -0.69 and a beta of 0.66.

Analyst Ratings Changes

A number of brokerages have commented on ATYR. Wall Street Zen raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Sunday. Jefferies Financial Group reaffirmed a “buy” rating on shares of aTyr Pharma in a research note on Friday, March 6th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $25.67.

Hedge Funds Weigh In On aTyr Pharma

Large investors have recently made changes to their positions in the company. California State Teachers Retirement System purchased a new position in shares of aTyr Pharma during the 2nd quarter worth about $28,000. Legal & General Group Plc bought a new stake in aTyr Pharma during the 2nd quarter valued at about $49,000. Prudential Financial Inc. bought a new stake in aTyr Pharma during the 2nd quarter valued at about $63,000. Oxford Asset Management LLP bought a new stake in aTyr Pharma during the 2nd quarter valued at about $70,000. Finally, Creative Planning bought a new stake in aTyr Pharma during the 2nd quarter valued at about $74,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.